论文部分内容阅读
目的研究趋化因子MCP-1在卵巢上皮性肿瘤中的表达,探讨MCP-1在卵巢肿瘤发生、发展中的作用及临床意义。方法采用半定量RT-PCR方法检测12例良性肿瘤、6例交界性卵巢肿瘤、22例卵巢癌原发病灶组织、8例卵巢癌转移病灶组织及10例正常卵巢组织中MCP-1mRNA的表达情况。结果正常卵巢组织、卵巢良性、交界性、恶性原发病灶组织及转移病灶组织中MCP-1表达的阳性率依次为25.0%、25.0%、50.0%、95.5%、87.5%,相对表达强度依次为0.11±0.01、0.18±0.03、0.51±0.05、0.73±0.08、0.45±0.08。MCP-1的阳性表达率和相对表达强度在卵巢交界性肿瘤中明显高于良性肿瘤,在卵巢恶性肿瘤中又明显高于交界性肿瘤,差异有统计学意义。MCP-1的表达与卵巢上皮癌组织学类型、组织分化及淋巴结转移情况无关,临床分期为Ⅲ～Ⅳ期的病例MCP-1的阳性表达率和相对表达强度与Ⅰ～Ⅱ期者相比,虽无显著性差异,但呈下降趋势。卵巢癌原发病灶组织中MCP-1的表达强度明显高于卵巢癌转移病灶组织,差异有统计学意义。MCP-1表达水平与肿瘤组织巨噬细胞浸润程度成正相关。结论MCP-1基因在卵巢肿瘤发生、发展过程中起重要作用。MCP-1可趋化和激活巨噬细胞而发挥抗肿瘤效应,因此MCP-1极可能成为卵巢恶性肿瘤治疗的效应分子。
Objective To study the expression of chemokine MCP-1 in ovarian epithelial tumors and to explore the role and clinical significance of MCP-1 in the development and progression of ovarian tumors. Methods The expression of MCP-1 mRNA in 12 cases of benign tumor, 6 cases of borderline ovarian tumor, 22 cases of primary ovarian cancer tissue, 8 cases of ovarian cancer metastasis and 10 cases of normal ovarian tissue were detected by semi-quantitative RT-PCR . Results The positive rates of MCP-1 in normal ovarian tissues, benign ovarian, borderline and malignant primary lesions and metastatic lesions were 25.0%, 25.0%, 50.0%, 95.5% and 87.5%, respectively. The relative expression intensity was 0.11 ± 0.01, 0.18 ± 0.03, 0.51 ± 0.05, 0.73 ± 0.08, 0.45 ± 0.08. The positive expression rate and relative expression intensity of MCP-1 in ovarian borderline tumors were significantly higher than those in benign tumors, and were significantly higher in borderline ovarian tumors than in borderline tumors. The difference was statistically significant. The expression of MCP-1 had no correlation with the histological type, tissue differentiation and lymph node metastasis of ovarian epithelial carcinoma. The positive expression rate and relative intensity of MCP-1 in cases with stage Ⅲ-Ⅳ clinical stage were significantly higher than those in stageⅠ-Ⅱ, Although no significant difference, but a downward trend. The expression of MCP-1 in primary ovarian cancer tissue was significantly higher than that in ovarian cancer metastatic lesions, the difference was statistically significant. The expression of MCP-1 positively correlated with the degree of macrophage infiltration in tumor tissue. Conclusion MCP-1 gene plays an important role in the development and progression of ovarian tumors. MCP-1 can chemotactic and activate macrophages to exert antitumor effects, so MCP-1 is highly likely to be an effector molecule for the treatment of ovarian malignancies.